Reaction
Endocrine Toxicity reporting signals
As of the last recalculation, Endocrine Toxicity appears in 99 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 229.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ipilimumab | 32 | 229.8 | 230.0 |
| Nivolumab | 46 | 186.0 | 186.1 |
| Durvalumab | 12 | 141.0 | 141.1 |
| Atezolizumab | 18 | 118.9 | 118.9 |
| Pemetrexed | 9 | 97.0 | 97.0 |